Drug Profile
Pivekimab sunirine - ImmunoGen
Alternative Names: IMGN-632; PVEK - ImmunoGenLatest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator ImmunoGen
- Developer Fred Hutchinson Cancer Research Center; ImmunoGen; Jazz Pharmaceuticals plc
- Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Indoles; Monoclonal antibodies; Pyrrolidines
- Mechanism of Action Alkylating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm
- Phase I Myelodysplastic syndromes
- No development reported Haematological malignancies
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 14 Dec 2023 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy, First-line therapy, Late-stage disease) in USA (IV) (NCT06034470)
- 14 Dec 2023 Phase-I clinical trials in Myelodysplastic syndromes (First-line therapy, Combination therapy, Late-stage disease) in USA (IV) (NCT06034470)